Business Wire

Medidata Solutions Broadens CRO Partner Accreditations to Field Increasing Product Demand

Share
NY-MEDIDATA-SOLUTIONS

Addition of Seven Accreditation Options Enables Services Partners to Support Wide Range of Medidata Clinical Research Technologies

Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that it has expanded its accreditation program for services partners to include seven additional Medidata products, in response to the increasing global demand for its product portfolio. The accreditations are available through the Medidata Partner Program, which selects and enables leading contract research organizations (CROs) and other service providers to manage sponsors’ clinical trials using Medidata products.

Since 2007, Medidata has offered partner accreditations for its Medidata Rave ® electronic data capture (EDC) and clinical data management (CDM) system, providing end user training, user and site administration, study build, reporting, outputs and migration services. With the growing number of global research sponsors implementing a range of Medidata products across the clinical development process, Medidata added the following accreditation options for Medidata Services Partners :

  • Medidata Balance ™— Partners are enabled to provide randomization and trial supply management (RTSM) services using this innovative system. Investigators can access one system—Medidata Rave—for EDC, randomization and supply management.
  • Medidata Coder ™— Partners offer medical coding services using this centralized enterprise coding solution that is easily integrated with any source system for accelerated coding activities.
  • Medidata CTMS ™— Partners can offer trial management services using modular and flexible tools for study planning, start-up and conduct, along with financial management and trial monitoring. Sponsors benefit from faster site payments, more timely monitor reporting and better visibility into trial milestones.
  • Medidata Designer ® Partners offer study design services leveraging this innovative study and protocol design solution based on reusable libraries and structured design information to improve protocol quality, expedite EDC setup and reduce amendments.
  • Medidata Grants Manager ® Partners use this trial budgeting tool for exclusive access to the PICAS®  database of negotiated costs from investigator grants to rapidly provide customers with accurate trial forecasts and budgets for clinical trials.
  • Medidata Rave Safety Gateway Partners automate their customers’ EDC-to-safety-system data transfers using this system to expedite case triage with improved accuracy and completeness of SAE case data, reduce data reconciliation activities and eliminate error-prone phone, paper and fax processes.
  • Medidata Rave Targeted SDV Partners can offer more efficient monitoring services using this EDC-based solution to execute targeted (risk-based) source document verification.

“As we continue to develop and enhance our product portfolio, there is a growing need to provide outsourcing organizations with the flexibility to add services that best complement their capabilities,” said Graham Bunn, vice president of partnerships, Medidata Solutions. “With these new accreditations, we can better enable our partners to provide greater value to sponsors on their outsourcing services, ultimately strengthening their strategic relationships.”

Medidata trains, accredits and supports Medidata Services Partners on its technology so partners can cost-effectively implement and use Medidata products for sponsors’ studies, allowing them to quickly realize the benefits of this technology. To become accredited, an organization must first complete required training with a Medidata services team to learn best practices for implementing and using the product. After demonstrating know-how and experience with specific products, Medidata recognizes the organization as a Medidata Services Partner.

Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer services in support of Medidata products. Since then, the program has grown to include about 30 partners, ranging from smaller clinical consultancies to large, global CROs.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Contact:

Lois Paul & Partners
Susan McCarron, 617-986-5767
Susan_McCarron@lpp.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA202515.6.2025 09:15:00 CEST | Press release

Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell productionIn high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic responsewith the majority (82%) realizing a complete responseA reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic responseInitial results demonstrate a favorable safety profile – no dose limiting toxicities were reported, a maximum tolerated dose was not reached and 98% of patients remained on treatmentIncyte will host an in-person analyst and investor event highlighting this data at EHA today, Sunday, June 15, 2025, from 6:00 - 7:30 a.m. EDT (12:00 -1:30 p.m. CEST) Incyte (Nasdaq:INCY) today announced the first

Perma-Pipe International Holdings, Inc. Announces First Quarter Fiscal 2025 Financial Results13.6.2025 15:14:00 CEST | Press release

The Company generated net sales of $46.7 million compared to $34.3 million in the first quarter of 2024Income before income taxes of $7.4 million versus $2.6 million in the first quarter of 2024Backlog of $131.1 million at April 30, 2025, compared to $63.1 million at April 30, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the first quarter ended April 30, 2025. “Sales for the first quarter were $46.7 million, resulting in an increase of $12.4 million, or 36.2%, compared to $34.3 million in the same quarter last year. Net income attributable to common stock of $5.0 million was an increase of $3.6 million, or 243%, compared to $1.4 million in the first quarter of the prior year,” noted President and CEO Saleh Sagr. Backlog currently stands at $131.1 million, a decrease of $7.0 million, compared to $138.1 million at January 31, 2025. However, the Company has experienced a significant increase in backlog of $68.0 million, or 108%, compare

Capcom’s Devil May Cry 5 Sales Top 10 Million Units!13.6.2025 15:00:00 CEST | Press release

– Capcom further enhances global brand awareness with its Single Content Multiple Usage strategy – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide cumulative sales of Devil May Cry 5 havesurpassed 10 million units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613788747/en/ Devil May Cry 5 logo In Devil May Cry 5, players can enjoy thrilling, high-speed gameplay, stylish action, and beautiful graphics, depicted with intricate realism thanks to Capcom’s proprietary RE ENGINE. The title has garnered strong support from users due to its exceptional gameplay experience, leading to expanded sales as a catalog title since its release. Capcom provided an even more advanced story and action elements in the game with the addition of a new playable character, and more recently, on April 3, 2025, the company released the new Devil May Cry animated series on Netflix, in line with the company’s Single Content Multiple Us

realme Summer Party: a Major Event and an Exclusive Collaboration with TikTok13.6.2025 14:59:00 CEST | Press release

realme, one of the world's leading smartphone brands, held a summer festival on June 6 and 7 at the foot of the Eiffel Tower with fun activities. Visitors could try their hand at ring throwing, immortalize their moments at the Photobooth van, or leave with exclusive gifts. Each participant received a voucher to exchange for a prize in the dedicated area for a successful festive experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612984325/en/ Live photo from realme Summer Party and the newly launched GT 7 Dream Edition A festive event at the foot of the Eiffel Tower The event was a great success, thanks to the engagement of participants on-site and through social media. Many visitors shared photos and videos, creating a dynamic and friendly atmosphere, amplified by the realme community. An exclusive collaboration between realme and TikTok This collaboration between realme and TikTok extends beyond this event. Indee

Take It Slow: Why Ireland Is the Perfect Destination for the ‘Unrushed’ Traveller13.6.2025 14:30:00 CEST | Press release

Tourism Ireland--In a world that’s always rushing, Ireland is extending a gentle invitation: take your time. With its winding coastal trails, soul-soothing landscapes, and deep-rooted traditions, Ireland is emerging as one of Europe’s most natural fits for slow tourism — a growing global travel trend focused on deeper, more meaningful experiences over fast-paced itineraries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612345730/en/ Cycling on greenway, County Waterford From misty mornings in the Burren to long afternoons along the Wild Atlantic Way, Ireland rewards those who slow down. Whether it’s connecting with local craftspeople, foraging along the coast, lingering over storytelling sessions in a pub, or staying in family-run farmhouses — the country’s charm reveals itself not in a rush, but in the details. What is ‘Slow Tourism’? Slow tourism encourages travellers to engage more fully with a destination, spending

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye